The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study

Diabetes is a common cause of chronic kidney disease (CKD), but in aggregate, non-diabetic diseases account for a higher proportion of cases of CKD than diabetes in many parts of the world. Inhibition of the renin–angiotensin system reduces the risk of kidney disease progression and treatments that...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Clin Kidney J
Huvudupphovsmän: Herrington, William G, Preiss, David, Haynes, Richard, von Eynatten, Maximilian, Staplin, Natalie, Hauske, Sibylle J, George, Jyothis T, Green, Jennifer B, Landray, Martin J, Baigent, Colin, Wanner, Christoph
Materialtyp: Artigo
Språk:Inglês
Publicerad: Oxford University Press 2018
Ämnen:
Sglt-2 Inhibition
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6275453/
https://ncbi.nlm.nih.gov/pubmed/30524708
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sfy090
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk